In contrast with previous reports (Bonadonna et al, 1990; Bottini et al, 1996; Chang et al, 1999; Colleoni et al, 2000), clinical response rates to PST were higher in hormone receptor-positive tumours in this cohort, although the difference did not reach statistical significance. This evidence concerns the gene NR4A1 and neoplasm.